Thus, PLZF is found to be a vital regulator of hepatic lipid metabolism, where the modulation of its liver expression may open up a therapeutic path for treating NAFLD. The gene discussed is ZBTB16; the disease is metabolic dysfunction-associated steatotic liver disease.